| Intervention | Indication/phenotype | Dosing | Outcome | Evidence type | MAXO suggestion | References |
|---|---|---|---|---|---|---|
| Pyridostigmine | ATR-X syndrome with gastrointestinal dysmotility: chronic constipation, abdominal distension, gastroparesis, reflux/feeding difficulty | Index ATR-X case: oral 30 mg/day (1.6 mg/kg/day) increased to 60 mg/day (3.2 mg/kg/day) | Symptom improvement reported; after 1 year of sustained treatment, gastrointestinal symptoms fully resolved | Human clinical case report + literature review | MAXO: gastrointestinal motility agent therapy; cholinesterase inhibitor therapy; constipation management | Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (pqac-00000014, pqac-00000016) |
| Pyridostigmine | Pediatric GI dysmotility in ATR-X and related severe dysmotility reports | Enteral 0.5 mg/kg twice daily, titrated to 1 mg/kg twice daily | Clinical improvement; improvement corroborated by abdominal X-ray in reported pediatric use | Human clinical literature summarized in review | MAXO: gastrointestinal motility agent therapy | Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (pqac-00000015) |
| Neostigmine followed by pyridostigmine | Severe GI dysmotility/intestinal pseudo-obstructive presentations in pediatric literature reviewed with relevance to ATR-X GI management | IV neostigmine 0.5 mg in 50 mL NS at 0.5 mg/hr for 10 days, then oral pyridostigmine 180 mg/day or 7 mg/kg/day | Reduced hospital length of stay and reduced dependence on parenteral nutrition; no side effects reported in these reviewed cases | Human clinical literature summarized in review | MAXO: acetylcholinesterase inhibitor therapy; intestinal pseudo-obstruction management | Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (pqac-00000015) |
| Supportive laxative therapy | Constipation/dysmotility in ATR-X syndrome | Senna, sodium picosulfate, docusate sodium (dose not specified) | No definitive effect in reported ATR-X case prior to pyridostigmine escalation | Human clinical case report | MAXO: laxative therapy; constipation management | Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (pqac-00000015) |
| Surgical/enteral supportive intervention | Severe gastroesophageal and nutritional complications in ATR-X syndrome | Laparoscopic anterior gastropexy plus button PEG-J (dose not applicable) | Reported improvement in nutrition and quality of life in literature summarized by review | Human clinical literature summarized in review | MAXO: gastrostomy tube placement; gastropexy; enteral nutrition support | Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (pqac-00000014) |
| Pyridostigmine safety summary | Pediatric GI dysmotility treatment safety | Across nine documented pediatric cases in the review; variable dosing | Only one patient had minor adverse events (abdominal pain/cramps); otherwise favorable tolerability | Human literature review | MAXO: adverse event monitoring during cholinesterase inhibitor therapy | Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (pqac-00000014, pqac-00000015) |
| 5-Aminolevulinic acid (5-ALA) | Exploratory treatment for cognitive dysfunction in ATR-X syndrome | 24-week phase 2 exploratory trial; exact dose not provided in retrieved evidence | 5 patients enrolled; 2/5 showed cognitive improvement; reported as safe and well tolerated; responders had higher blood 5-ALA/PpIX concentrations | Early human clinical trial + preclinical rationale | MAXO: developmental disability treatment; experimental metabolic therapy; cognitive symptom management | Evidence summarized in 2025 review citing phase 2 trial data (pqac-00000018) |


*Table: This table summarizes reported management evidence for ATR-X syndrome, emphasizing gastrointestinal dysmotility interventions and the exploratory 5-ALA cognitive trial. It is useful for distinguishing supportive care from early experimental therapy and for mapping interventions to MAXO-style treatment concepts.*